Canertinib (CI-1033; PD-183805)

Description: Canertinib (formerly CI-1033; CI1033; PD183805; PD-183805) is an irreversible/covalent, quinazoline-based and orally bioavailable pan-ErbB inhibitor for EGFR and ErbB2 with potential antineoplastic activity. It inhibits EGFR and ErbB2 with IC50s of 1.5 nM and 9.0 nM, respectively, but shows no activity against PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine (ErbB) kinases irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents.

References: J Med Chem. 2000 Apr 6; 43(7):1380-97; Semin Oncol. 2001 Oct; 28(5 Suppl 16):80-5.

Related CAS: 267243-28-7 (free base); 289499-45-2 (HCl)

Chemical Name: N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide

InChi Key: OMZCMEYTWSXEPZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2, 4-5, 12-15H, 1, 3, 6-11H2, (H, 30, 32)(H, 27, 28, 29)

SMILES Code: C=CC(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN4CCOCC4)=O